
Vaxcyte (PCVX) Stock Forecast & Price Target
Vaxcyte (PCVX) Analyst Ratings
Bulls say
Vaxcyte is in a strong position as its lead vaccine candidate, VAX-31 for PCV, has a high probability of success with an efficient and precise coupling technology. Its broad spectrum design targets serotypes in circulation associated with high case-fatality rates, antibiotic resistance, and meningitis, addressing clinically and commercially relevant gaps. With a strong financial position and multiple potential catalysts in the near-term, Vaxcyte presents a promising investment opportunity in the competitive vaccine market.
Bears say
Vaxcyte is facing potential challenges with the recent CDC decision to recommend fewer vaccines, as it could lead to decreased demand and usage of their products. Additionally, the company's current pipeline has several novel vaccines in development, which may face competition when they become established. Finally, the success of their lead candidate VAX-31 may depend on strict immunogenicity criteria, potentially hindering future competitors.
This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.
Vaxcyte (PCVX) Analyst Forecast & Price Prediction
Start investing in Vaxcyte (PCVX)
Order type
Buy in
Order amount
Est. shares
0 shares